Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 1,601–1,700 of 4,108
Miller, K. L., Steffen, M. J. A., McCoy, K. D., Cannon, G. W., Seaman, A. T., Anderson, Z. L., Patel, S. A., Green, J., Wardyn, S. E., & Solimeo, S. L. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00882-0 · Cited by 13
Kim, K. J., Kim, M. S., Hong, N., Bae, J. H., Kim, K. J., Kim, N. H., Rhee, Y., Lee, J., & Kim, S. G. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab054 · Cited by 14
Metabolic bone diseases in sickle cell anemia patients and evaluation of associated factors
Eskiocak, Ö., Yılmaz, M. Ö., & İlhan, G. (2021) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.07.002 · Cited by 13
Radiographic diagnosis of osteoporotic vertebral fractures. An updated review
Zúñiga, D. L., Ramos‐Bossini, A. J. L., & Santiago, F. R. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.06.019 · Cited by 13
Transdermal formulations and strategies for the treatment of osteoporosis
Villanueva-Martínez, A., Merino, V., & Ganem‐Rondero, A. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103111 · Cited by 14
Dowhan, L., & Dharmarajan, T. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-30192-7_26 · Cited by 17
Park, J. M., Lee, B., Kim, Y., Hong, K., Park, Y. C., Shin, D. H., Kim, Y., Han, K., Kim, K. Y., Shin, J., et al. (2022) · Nutrients · doi:10.3390/nu14122538 · Cited by 16
Holmberg, T., Rubin, K. H., Brixen, K., Tolstrup, J. S., & Bech, M. (2013) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2013.03.014 · Cited by 13
Machine Learning to Predict Osteoporotic Fracture Risk from GenotypesPreprint
Forgetta, V., Keller‐Baruch, J., Forest, M., Durand, A., Bhatnagar, S., Kemp, J. P., Morris, J. A., Kanis, J. А., Kiel, D. P., McCloskey, E. V., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/413716 · Cited by 15
Menopause and gastrointestinal health and disease
Ley, D., & Saha, S. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01075-7 · Cited by 19
Mirza, R. D., El-Rabbany, M., Ali, D. S., Tetradis, S., Morrison, A., Ruggiero, S. L., Alnajimi, R., Khan, A. A., & Guyatt, G. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.003 · Cited by 17
Mocini, E., Piciocchi, C., Defeudis, G., & Migliaccio, S. (2025) · Gerontology · doi:10.1159/000546501 · Cited by 21
“Osteoporosis is primarily diagnosed using dual-energy X-ray absorptiometry, which measures BMD, with a T score of −2.5 or lower confirming the diagnosis [6].”
InfluentialVariability in DXA Reporting and Other Challenges in Osteoporosis Evaluation
Kim, T. Y., & Schafer, A. L. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.7550 · Cited by 12
Themes and trends for osteoporosis: the bibliometric and altmetric approach
Suzan, V., Kanat, B. B., Yavuzer, H., & Döventaş, A. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00983-w · Cited by 12
Haffer, H. P. H., Chiapparelli, E. A., Moser, M., Muellner, M., Dodo, Y., Amini, D. A., Zhu, J., Miller, T. T., Han, Y. X., Donnelly, E. L., et al. (2022) · Journal of Orthopaedic Research® · doi:10.1002/jor.25350 · Cited by 13
“One of the most established methods of determining bone strength is the quantitative measurement of the bone mineral density (BMD) using dual‐energy X‐ray absorptiometry (DXA).(7,8) However, it is recognized that BMD is not the sole predictive factor to assess fracture risk.”
MethodRelationship between bone density and levetiracetam monotherapy in epilepsy patients
Gözükızıl, S. T., Aydın, Z., & Yalçın, A. D. (2022) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2022.107270 · Cited by 14
Wang, M., Wu, Y. Q., Zhou, Y., Dong, J., Hu, S., Hou, P., & Gao, J. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s381857 · Cited by 12
“Bone mineral density (BMD) measurement is an important indicator in osteoporosis diagnosis, fracture risk prediction, and treatment effect evaluation.(6,7) Therefore, accurate and convenient BMD measurement is of great clinical and research interest.”
BackgroundKanis, J. А., Johansson, H., Harvey, N. C., Gudnason, V. G., Sigurðsson, G., Siggeirsdóttir, K., Lorentzon, M., Liu, E., Vandenput, L., & McCloskey, E. V. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06550-4 · Cited by 13
Xu, G., Wang, D., Zhang, H., Xu, C., Li, H., Zhang, W., Li, J., Zhang, L., & Tang, P. (2023) · Frontiers in Surgery · doi:10.3389/fsurg.2022.1047603 · Cited by 13
“After the osteoporotic patients were selected, the initiation of osteoporotic treatment should be considered for preventing the happen of osteoporotic fractures (32).”
BackgroundHassan, A. M., Haridy, M. A., Shoaeir, M. Z., Abdel-Aziz, T. M., Qura, M. K., Kenawy, E. M., Mansour, T. M. M., Elsayed, S. S., Ali, W. E., Abdelmeguid, M. M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-31256-w · Cited by 17
A narrative review of the pharmaceutical management of osteoporosis
Patel, D., Gorrell, C., Norris, J., & Liu, J. (2023) · Annals of Joint · doi:10.21037/aoj-23-2 · Cited by 16
“After diagnosis and initiation of therapy, BMD testing should be repeated every two years, and more often in the case of recurring fractures (10).”
Exposure to Neighborhood Walkability and Residential Greenness and Incident Fracture
Zhu, Z., Yang, Z., Xu, L., Wu, Y., Yu, L., Shen, P., Lin, H., Shui, L., Tang, M., Jin, M., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.35154 · Cited by 15
Up-regulation of plasma miRNA-21 and miRNA-422a in postmenopausal osteoporosis
Mohammadisima, N., Farshbaf‐Khalili, A., & Ostadrahimi, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287458 · Cited by 14
Osteoporosis Prediction Using Machine-Learned Optical Bone Densitometry Data
Miura, K., Tanaka, S. M., Chotipanich, C., Chobpenthai, T., Jantarato, A., & Khantachawana, A. (2023) · Annals of Biomedical Engineering · doi:10.1007/s10439-023-03387-8 · Cited by 16
Tang, Y., Dong, W., Shen, J., Jiang, G., Wang, Q., Hao, J., & Hu, Z. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01368-5 · Cited by 11
“Moreover, early recognition of the lifestyle and behavioral factors for osteoporosis has enabled the prompt identification of individuals at high risk for osteoporosis, thereby providing evidence for targeted interventions and lifestyle modifications [13].”
Wei, Q., Zhou, Y., Hu, Z., Shi, Y., Ning, Q. X., Ren, K., Guo, X., Zhong, R., Xia, Z., Yin, Y., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118130 · Cited by 15
Drug-induced osteoporosis and mechanisms of bone tissue regeneration through trace elements
da Costa, N. D. S., Lima, L. S., Galiciolli, M. E. A., Ribeiro, D. H. F., Ribeiro, M. M., Garica, G. D. P. J., Marçal, I. S., da Silva, J. F., Pereira, M. E., Oliveira, C. S., et al. (2024) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2024.127446 · Cited by 15
Peptide Drugs: Current Status and it's Applications in the Treatment of Various Diseases
Chandarana, C. V., Juwarwala, I., Shetty, S., & Bose, A. (2024) · Current Drug Research Reviews · doi:10.2174/0125899775295960240406073630 · Cited by 14
Runting, H., Qingyue, L., Yining, Y., Huiyu, S., Shu, Y., & Xixi, F. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1396007 · Cited by 14
“In the United States alone, approximately 2 million fractures are attributed to osteoporosis annually, with projected healthcare costs reaching $25.3 billion by 2025 (5).”
BackgroundInfluentialZhu, G., Guo, B., & Liang, J. (2024) · Bone · doi:10.1016/j.bone.2024.117255 · Cited by 15
Wang, S.-T., Gu, H.-Y., Huang, Z.-C., Li, C., Liu, W.-N., & Li, R. (2025) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2025.105029 · Cited by 14
Khan, M. A., Khan, M. A., Siddiqui, S., Misra, A., Yadav, K., Srivastava, A., Trivedi, A., Husain, I., & Ahmad, R. (2025) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2025.106740 · Cited by 16
He, X., Whitmore, G. A., Loo, G. Y., Hochberg, M. C., & Lee, M. T. (2014) · Statistics in Medicine · doi:10.1002/sim.6356 · Cited by 12
Survey of risk factors for osteoporosis and osteoprotective behaviors among patients with epilepsy
Fedorenko, M., Wagner, M., & Wu, B. Y. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.01.021 · Cited by 12
Watts, N. B. (2013) · Endocrine Practice · doi:10.4158/ep13114.ra · Cited by 14
Effects of Mometasone, Fluticasone, and Montelukast on Bone Mineral Density in Adults with Asthma
Maspero, J. F., Backer, V., Yao, R., Staudinger, H. W., & Teper, A. A. (2013) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2013.07.011 · Cited by 12
Sanfélix‐Gimeno, G., Hurtado, I., Sanfélix‐Genovés, J., Baixauli, C. G., Rodríguez-Bernal, C. L., & Peiró, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135475 · Cited by 14
Jiang, Y., & Ni, W. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0724-9 · Cited by 13
North, F., Fox, S. C., & Chaudhry, R. (2016) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-016-0334-z · Cited by 12
Pisani, P., Conversano, F., Chiriacò, F., Quarta, E., Quarta, L., Muratore, M., Lay-Ekuakille, A., & Casciaro, S. (2016) · Measurement · doi:10.1016/j.measurement.2016.08.014 · Cited by 12
Bhat, K. A., Kakaji, M., Awasthi, A., Shukla, M. K., Dubey, M. K., Srivastava, R. K., Singh, U., & Gupta, S. K. (2016) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2016.10.003 · Cited by 17
Effects of clinical reanalysis in dual energy X-ray absorptiometry reports
Tuna, F., Yavuz, S., Kabayel, D. D. D., & Sarıkaya, A. (2017) · Turkish Journal of Physical Medicine and Rehabilitation · doi:10.5606/tftrd.2017.595 · Cited by 11
Optimizing calcium and vitamin D intake through diet and supplements
Kilim, H. P., & Rosen, H. N. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.17106 · Cited by 15
Academic Geriatric Orthopedics: a New Paradigm for Inpatient Care
Quatman, C. E., Wiseman, J. M., & Phieffer, L. S. (2018) · Current Geriatrics Reports · doi:10.1007/s13670-018-0266-9 · Cited by 13
Ye, C., Guo, Y.-B., Zheng, Y., Wu, Z., Chen, K., Zhang, X., Xiao, L., & Chen, Z. (2020) · Injury · doi:10.1016/j.injury.2020.08.018 · Cited by 12
Kolz, J. M., Mitchell, S. A., Elder, B. D., et al. (2020) · Global Spine Journal · doi:10.1177/2192568220950332 · Cited by 12
“This highlights the importance of preoperative bone density evaluation and treatment to help prevent any osteoporosis related complications after lumbosacral fusion.(45,46) Last, the inherent biomechanics of the L5-S1 level may increase sacral fracture risk.”
BackgroundPharmacological management of osteoporosis in nursing home residents: the Shelter study
Makan, A. M., van Hout, H. P. J., Onder, G., van der Roest, H. G., Finne‐Soveri, H., Topinková, E., Denkinger, M. D., Gindin, J., & van Marum, R. J. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.10.020 · Cited by 12
FRAX-based osteoporosis treatment guidelines for resource-poor settings in India
Nagendra, L., Bhavani, N., Menon, V. U., Pavithran, P. V., Menon, A. S., Abraham, N., Nair, V., & Kumar, H. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00931-8 · Cited by 13
Boonyayothin, W., Sinnung, S., Shanmugaraj, B., Abe, Y., Strasser, R., Pavasant, P., & Phoolcharoen, W. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.683417 · Cited by 13
“Osteoporosis is a common skeletal disease caused by an imbalance in the bone remodeling process (or bone metabolism; Lewiecki, 2010b; Cosman et al., 2014).”
BackgroundRelevance of vitamin D3 in COVID-19 infection
Afshan, F. U., Nissar, B., Chowdri, N. A., & Ganai, B. A. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101270 · Cited by 14
Özsoy-Ünübol, T., Candan, Z., Atar, E., Ok, N. F., Ata, E., Kilaç, H., & Yılmaz, F. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14851 · Cited by 15
Chronic pain in older and senile patients. Clinical guidelines
Tkacheva, O. N., Naumov, A. V., Kotovskaya, Y. V., Рунихина, Н. К., Milto, A. S., Alexanyan, L. A., Khovasova, N. O., Мороз, В. И., Маневич, Т. М., Розанов, А. В., et al. (2021) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-3-2021-275-312 · Cited by 15
Treatment of cystic fibrosis related bone disease
Ullal, J., KUTNEY, K. A., Williams, K. M., & Weber, D. R. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100291 · Cited by 15
“The National Osteoporosis Foundation guidelines are not CF specific but offer recommendations for this age group [12].”
BackgroundJamshidi, A., Vojdanian, M., Soroush, M. G. Z., Akbarian, M., Aghaei, M., Hajiabbasi, A., Mirfeizi, Z., Khabbazi, A., Alishiri, G. H., Haghighi, A., et al. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02840-8 · Cited by 18
“Postmenopausal osteoporosis guidelines highly recommend pharmacologic treatment in patients with osteoporosis and patients with osteopenia at high risk for fractures [7, 8].”
BackgroundLivingstone, S. J., Morales, D. R., McMinn, M., Eke, C. S., Donnan, P. T., & Guthrie, B. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2022-000316 · Cited by 14
Chang, E., Binkley, N., Krueger, D. C., Illgen, R. L., Nickel, B. T., Hennessy, D., Bernatz, J. T., Winzenried, A. E., & Anderson, P. A. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06585-7 · Cited by 12
“1 3 and a BMD-adjusted MOF risk ≥ 20% or hip fracture risk ≥ 3%, or a history of hip or spine fracture [19].”
BackgroundFerreira, P., Bates, P., Daoub, A., & Dass, D. (2022) · Orthopaedics & Traumatology Surgery & Research · doi:10.1016/j.otsr.2022.103475 · Cited by 14
Miglietta, F., Iamartino, L., Palmini, G., Giusti, F., Marini, F., Iantomasi, T., & Brandi, M. L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1085315 · Cited by 15
Radecka, A., & Lubkowska, A. (2023) · Diagnostics · doi:10.3390/diagnostics13091576 · Cited by 17
Demirtas, A., Taylor, E. A., Gludovatz, B., Ritchie, R. O., Donnelly, E. L., & Ural, A. (2023) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2023.106034 · Cited by 14
Ren, X., Hu, C., Wang, W., He, Q., Du, L., Li, T., Pan, Y., Chen, S., & Zhang, X. (2024) · Bone · doi:10.1016/j.bone.2024.117025 · Cited by 12
Baccaro, L. F., Machado, V. D. S. S., Costa‐Paiva, L., et al. (2013) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1590/s0100-72032013001100004 · Cited by 12
Diagnosis and Management of Osteoporosis
Patel, I., & Zaro, S. (2012) · InnovAiT Education and inspiration for general practice · doi:10.1093/innovait/ins123 · Cited by 13
Kaats, G. R., Preuss, H. G., Croft, H. A., Keith, S. C., & Keith, P. L. (2011) · International Journal of Medical Sciences · doi:10.7150/ijms.8.180 · Cited by 12
Hurtado, I., Sanfélix‐Gimeno, G., Baixauli, C. G., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3448 · Cited by 12
Xu, Z., Hao, D., He, L., et al. (2015) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2015.09.006 · Cited by 12
HUBUNGAN ASUPAN PROTEIN, FOSFOR, DAN KALSIUM DENGAN KEPADATAN TULANG PADA WANITA DEWASA AWAL
Faizah, L. N., & Fitranti, D. Y. (2015) · Journal of Nutrition College · doi:10.14710/jnc.v4i4.10106 · Cited by 12
Helicobacter pylori : A Possible Risk Factor for Bone Health
Chung, Y. H., Gwak, J. S., Hong, S. W., Hyeon, J. H., Lee, C. M., Oh, S., & Kwon, H. (2015) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2015.36.5.239 · Cited by 12
López, E., Ibarz, E., Herrera, A., Puértolas, S., Gabarre, S., Más, Y., Mateo, J., Albarova, J. G., & Gracia, L. (2016) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2016.04.006 · Cited by 12
Almstedt, H. C., Grote, S., Perez, S. E., Shoepe, T. C., Strand, S., & Tarleton, H. P. (2016) · European Journal of Cancer Care · doi:10.1111/ecc.12442 · Cited by 14
Recent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short?
Barnard, K., Lakey, W. C., Batch, B. C., Chiswell, K., Tasneem, A., & Green, J. B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156068 · Cited by 11
Forearm bone mass predicts mortality in chronic hemodialysis patients
Orlić, L., Mikolašević, I., Crnčević-Orlić, Ž., Jakopčić, I., Josipović, J., & Pavlović, D. (2016) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-016-0766-7 · Cited by 14
How do you decide on hormone replacement therapy in women with risk of venous thromboembolism?
Leković, D., Miljić, P., Dmitrović, A., & Thachil, J. V. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.12.001 · Cited by 11
The Future of Fracture Risk Assessment in the Management of Osteoporosis
Baim, S. (2017) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2017.06.015 · Cited by 12
The Management of Osteoporosis After Fragility Fracture: The Orthopaedic Perspective
Morris, J., Karkenny, A. J., & Toro, J. B. (2017) · JBJS Reviews · doi:10.2106/jbjs.rvw.16.00098 · Cited by 16
Preventive Health for Transgender Men and Women
Graf, E., McCune, K. C., & Imborek, K. L. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1604457 · Cited by 18
The Good and the Bad About the 2017 American College of Physicians Osteoporosis Guidelines
Lagari, V. S., Gavcovich, T. B., & Levis, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.11.008 · Cited by 12
Mao, Y. V., Zhang, Y., Li, K., et al. (2018) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2018.08.007 · Cited by 12
Sun, Y., Dai, W., Liang, Y., Yang, P., Yang, Q., Liang, M., & Xia, N. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s192256 · Cited by 15
Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review
Iqbal, S. M., Qamar, I., Zhi, C., Nida, A., & Aslam, H. M. (2019) · Cureus · doi:10.7759/cureus.4146 · Cited by 14
Beshyah, S., Al‐Saleh, Y., & Fuleihan, G. E. (2019) · Archives of Osteoporosis · doi:10.1007/s11657-019-0609-y · Cited by 14
Personalising osteoporosis treatment for patients at high risk of fracture
Khosla, S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30266-9 · Cited by 13
Corrigan, M. A., Coyle, S., Eichholz, K. F., Riffault, M., Lenehan, B. J., & Hoey, D. A. (2019) · Cells Tissues Organs · doi:10.1159/000503444 · Cited by 15
Quality Measures and Quality Improvement Initiatives in Osteoporosis—an Update
French, S., Choden, S., & Schmajuk, G. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00547-5 · Cited by 13
Yamanaka, Y., Menuki, K., Zenke, Y., et al. (2019) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2019.11.002 · Cited by 12
Campbell, A., Coley, K. C., Corbo, J. M., DeLellis, T., Joseph, M., Thorpe, C. T., McGivney, M. S., Klatt, P. M., Cox-Vance, L., Balestrino, V., et al. (2018) · Europe PMC (PubMed Central) · Cited by 12
Jazinizadeh, F., & Quenneville, C. E. (2020) · Annals of Biomedical Engineering · doi:10.1007/s10439-020-02670-2 · Cited by 16
Osteoporosis Diagnosis and Management
Pope, R. S., & Doback, J. (2020) · Physician Assistant Clinics · doi:10.1016/j.cpha.2020.09.009 · Cited by 13
Asymptomatic elevated parathyroid hormone level due to immunoassay interference
Zanchetta, M. B., Giacoia, E., Jerkovich, F., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05950-2 · Cited by 12
Alfieri, C., Binda, V., Malvica, S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091989 · Cited by 12
Prevalence of osteoporosis in elderly women in Hong Kong
Lo, S. S. T. (2021) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2021.09.001 · Cited by 12
Pharmacologic Management of Osteoporosis
Fontenot, H. B., & Harris, A. L. (2014) · Journal of Obstetric, Gynecologic & Neonatal Nursing · doi:10.1111/1552-6909.12285 · Cited by 12
Cass, A. R., Shepherd, A. J., Asirot, R. L., Mahajan, M., & Nizami, M. M. U. I. (2016) · The Annals of Family Medicine · doi:10.1370/afm.1945 · Cited by 14
Jeon, Y., Kim, B., & Kim, I. (2016) · Journal of Korean Medical Association · doi:10.5124/jkma.2016.59.11.842
Long‐Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative
Drieling, R. L., LaCroix, A. Z., Beresford, S. A. A., Boudreau, D. M., Kooperberg, C. L., Chlebowski, R. T., Ko, M. G., & Heckbert, S. R. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14911 · Cited by 12
Silva, D. M. W., Borba, V. Z. C., & Kanis, J. А. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0405-5 · Cited by 13
hPTH(3-34)(29-34) selectively activated PKC and mimicked osteoanabolic effects of hPTH(1-34)
He, Y., Li, M., Tong, G., et al. (2020) · Bone · doi:10.1016/j.bone.2020.115326 · Cited by 12
The story of amylin: from physiology to therapy
Secher, A., Lutz, T. A., & Raun, K. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01465-4 · Cited by 16
Molina, J. F., Molina, J., Escobar, J. A., et al. (2019) · Acta Médica Colombiana · doi:10.36104/amc.2011.1512 · Cited by 11
Izuora, K. E., Tangpricha, V., Nanes, M. S., Alazraki, N. P., & Byrd-Sellers, J. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31820aba02 · Cited by 11
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.